ID

14455

Beschreibung

Phase IIb Randomized Controlled Study of BLP25 Liposome Vaccine for Immunotherapy of Non-Small Cell Lung Cancer; ODM derived from: https://clinicaltrials.gov/show/NCT00157209

Link

https://clinicaltrials.gov/show/NCT00157209

Stichworte

  1. 15.04.16 15.04.16 -
Hochgeladen am

15. April 2016

DOI

Für eine Beantragung loggen Sie sich ein.

Lizenz

Creative Commons BY 4.0

Modell Kommentare :

Hier können Sie das Modell kommentieren. Über die Sprechblasen an den Itemgruppen und Items können Sie diese spezifisch kommentieren.

Itemgroup Kommentare für :

Item Kommentare für :


Keine Kommentare

Um Formulare herunterzuladen müssen Sie angemeldet sein. Bitte loggen Sie sich ein oder registrieren Sie sich kostenlos.

Eligibility Lung Neoplasms NCT00157209

Eligibility Lung Neoplasms NCT00157209

Inclusion Criteria
Beschreibung

Inclusion Criteria

Alias
UMLS CUI
C1512693
stage iiib or stage iv nsclc
Beschreibung

NSCLC staging

Datentyp

boolean

Alias
UMLS CUI [1]
C0278984
UMLS CUI [2]
C0278987
stable disease or a clinical response following first-line treatment, consisting of either chemotherapy alone or chemotherapy and radiotherapy. patients must have completed the first-line treatment at least 3 weeks prior to study entry
Beschreibung

Treatment details

Datentyp

boolean

Alias
UMLS CUI [1]
C1704632
UMLS CUI [2]
C1708063
UMLS CUI [3]
C0392920
UMLS CUI [4]
C3839414
UMLS CUI [5]
C0580352
ecog performance status of ≤2
Beschreibung

ECOG performance status

Datentyp

boolean

Alias
UMLS CUI [1]
C1520224
ability to understand and willingness to sign a written informed consent
Beschreibung

Informed consent

Datentyp

boolean

Alias
UMLS CUI [1]
C0021430
Exclusion Criteria
Beschreibung

Exclusion Criteria

Alias
UMLS CUI
C0680251
received immunotherapy within 4 weeks prior to study entry
Beschreibung

Immunotherapy: date

Datentyp

boolean

Alias
UMLS CUI [1]
C0021083
UMLS CUI [2]
C2584899
received immunosuppressive drugs within 3 weeks prior to study entry
Beschreibung

Immunosupression: date

Datentyp

boolean

Alias
UMLS CUI [1,1]
C0021079
UMLS CUI [1,2]
C2584899
patients with known brain metastases
Beschreibung

Brain metastases

Datentyp

boolean

Alias
UMLS CUI [1]
C0220650
past or current history of neoplasm other than lung carcinoma, except for curatively treated non-melanoma skin cancer, in situ carcinoma of the cervix or other cancer curatively treated and with no evidence of disease for at least 5 years
Beschreibung

Further malignancies

Datentyp

boolean

Alias
UMLS CUI [1,1]
C0006826
UMLS CUI [1,2]
C0332196
UMLS CUI [1,3]
C0007114
UMLS CUI [2,1]
C0006826
UMLS CUI [2,2]
C0332196
UMLS CUI [2,3]
C2216722
UMLS CUI [3,1]
C0006826
UMLS CUI [3,2]
C0332196
UMLS CUI [3,3]
C0242793
autoimmune disease or immunodeficiency
Beschreibung

Autoimmune disease or immunodeficiency

Datentyp

boolean

Alias
UMLS CUI [1]
C0004364
UMLS CUI [2]
C0021051
clinically significant hepatic, renal or cardiac dysfunction
Beschreibung

Liver, renal and cardiac function

Datentyp

boolean

Alias
UMLS CUI [1]
C0232741
UMLS CUI [2]
C0232804
UMLS CUI [3]
C0232164
patients with clinically significant active infection
Beschreibung

Infection

Datentyp

boolean

Alias
UMLS CUI [1]
C0009450
pregnant or breast feeding women, women of childbearing potential, unless using effective contraception as determined by the investigator
Beschreibung

Gynaecological status

Datentyp

boolean

Alias
UMLS CUI [1]
C0032961
UMLS CUI [2]
C3831118
UMLS CUI [3]
C0006147
UMLS CUI [4]
C0700589

Ähnliche Modelle

Eligibility Lung Neoplasms NCT00157209

Name
Typ
Description | Question | Decode (Coded Value)
Datentyp
Alias
Item Group
C1512693 (UMLS CUI)
NSCLC staging
Item
stage iiib or stage iv nsclc
boolean
C0278984 (UMLS CUI [1])
C0278987 (UMLS CUI [2])
Treatment details
Item
stable disease or a clinical response following first-line treatment, consisting of either chemotherapy alone or chemotherapy and radiotherapy. patients must have completed the first-line treatment at least 3 weeks prior to study entry
boolean
C1704632 (UMLS CUI [1])
C1708063 (UMLS CUI [2])
C0392920 (UMLS CUI [3])
C3839414 (UMLS CUI [4])
C0580352 (UMLS CUI [5])
ECOG performance status
Item
ecog performance status of ≤2
boolean
C1520224 (UMLS CUI [1])
Informed consent
Item
ability to understand and willingness to sign a written informed consent
boolean
C0021430 (UMLS CUI [1])
Item Group
C0680251 (UMLS CUI)
Immunotherapy: date
Item
received immunotherapy within 4 weeks prior to study entry
boolean
C0021083 (UMLS CUI [1])
C2584899 (UMLS CUI [2])
Immunosupression: date
Item
received immunosuppressive drugs within 3 weeks prior to study entry
boolean
C0021079 (UMLS CUI [1,1])
C2584899 (UMLS CUI [1,2])
Brain metastases
Item
patients with known brain metastases
boolean
C0220650 (UMLS CUI [1])
Further malignancies
Item
past or current history of neoplasm other than lung carcinoma, except for curatively treated non-melanoma skin cancer, in situ carcinoma of the cervix or other cancer curatively treated and with no evidence of disease for at least 5 years
boolean
C0006826 (UMLS CUI [1,1])
C0332196 (UMLS CUI [1,2])
C0007114 (UMLS CUI [1,3])
C0006826 (UMLS CUI [2,1])
C0332196 (UMLS CUI [2,2])
C2216722 (UMLS CUI [2,3])
C0006826 (UMLS CUI [3,1])
C0332196 (UMLS CUI [3,2])
C0242793 (UMLS CUI [3,3])
Autoimmune disease or immunodeficiency
Item
autoimmune disease or immunodeficiency
boolean
C0004364 (UMLS CUI [1])
C0021051 (UMLS CUI [2])
Liver, renal and cardiac function
Item
clinically significant hepatic, renal or cardiac dysfunction
boolean
C0232741 (UMLS CUI [1])
C0232804 (UMLS CUI [2])
C0232164 (UMLS CUI [3])
Infection
Item
patients with clinically significant active infection
boolean
C0009450 (UMLS CUI [1])
Gynaecological status
Item
pregnant or breast feeding women, women of childbearing potential, unless using effective contraception as determined by the investigator
boolean
C0032961 (UMLS CUI [1])
C3831118 (UMLS CUI [2])
C0006147 (UMLS CUI [3])
C0700589 (UMLS CUI [4])

Benutzen Sie dieses Formular für Rückmeldungen, Fragen und Verbesserungsvorschläge.

Mit * gekennzeichnete Felder sind notwendig.

Benötigen Sie Hilfe bei der Suche? Um mehr Details zu erfahren und die Suche effektiver nutzen zu können schauen Sie sich doch das entsprechende Video auf unserer Tutorial Seite an.

Zum Video